MiMedx Group stock
MDXGNASDAQMiMedx Group, Inc., HealthcareISIN US6024961012
37Score 37 out of 100, Weak
Price and trend
37 / 100
Price history
−57% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 22% below it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 23).
The price is 57% below its 52-week high. Largest decline in 19 years: 94% (March 2008 to March 2009).
Chart figures for advanced users
- SMA 50$4.28
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.18
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)23
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.09
- The lowest closing price of the last twelve months.
- Resistance$7.48
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- MiMedx Group, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $472.8M, is number 245 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $418.63M (up 20% year on year) and earnings of $48.58M (up 14.5%).
- For fiscal 2026, analysts expect on average revenue of $255.87M (down 38.9%) and adjusted earnings per share of −$0.12.
Show more
- MEQIRI Score 37 out of 100 (Weak): rank 579 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 41.4% in fiscal 2025, Biotechnology median −24.3%.
- More cash than debtCash $120.79M, financial debt $0.Stability 85
Weaknesses
- DilutionShare count up 37% since 2020.Capital allocation 18
- Loss-makingLoss of $19.19M over the last 12 months.Fundamentals 28
- Share price fell sharplyDown 57% over the last 12 months.Momentum 21
Its standout strength is stability, while momentum and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 22.8% on the twelve months before. Revenue turned from negative at the start of the period to positive ($418.63M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 83%, operating 15%, net 12%. Last 12 months: net −6%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 28 Oct 2026EPS reported −$0.01 (expected $0.00)below expectations
Analyst estimates
- Earnings per share
- −$0.12−53.3%
- Revenue
- $255.87M−4.2%
- Earnings per share
- $0.07−42.5%
- Revenue
- $302.43M−6.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: +1.8%MiMedx lowered its stand-alone 2026 outlook to net sales of $250 million to $260 million, after third quarter sales of $62.3 million came in well below expectations.
“We are updating our stand-alone 2026 outlook and now expect full year net sales of $250 million to $260 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at MiMedx Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Phathom PharmaceuticalsPHAT $506.45M29
- DiaMedica TherapeuticsDMAC $503.13M46
- Shattuck LabsSTTK $489.86M31
- Ovid TherapeuticsOVID $481.27M43
- Hansa BiopharmaHNSA.ST $472.24M47
- Oculis HoldingOCS $462.99M30
- Gyre TherapeuticsGYRE $455.95M35
- ArvinasARVN $449.88M37
ETFs that hold MiMedx Group
Held by 4 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.03% | 0.40% | €813.42M |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.02% | 0.39% | €1.49B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
Show 1 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.